Trials / Completed
CompletedNCT00578955
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 417 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1% Azithromycin and 0.1% Dexamethasone | Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes. |
| DRUG | 1% Azithromycin | Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes. |
| DRUG | 0.1% Dexamethasone | Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-12-21
- Last updated
- 2021-11-19
Source: ClinicalTrials.gov record NCT00578955. Inclusion in this directory is not an endorsement.